Skip to content

Neuroplastic white matter changes in patients with major depression following lysergic acid diethylamide treatment

Mihai Avram, Aurore Menegaux, Felix Müller, Hannes Zaczek, Alexandra Korda, Helena Rogg, Anna M Becker, Laura Ley, Matthias E. Liechti, Stefan Borgwardt

Cell Reports Medicine May 7, 2026 DOI: 10.1016/j.xcrm.2026.102791 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Sample size 35
Population Patients with major depressive disorder (MDD)
Intervention Lysergic acid diethylamide (LSD)
Dose 100 μg followed by 200 μg (moderate-to-high-dose) or 2 × 25 μg (low-dose)
Duration 4 weeks apart (intervention), with follow-up at 2, 6, and 12 weeks
Topics LSD Neuroplasticity Depression
Keywords Depression economics White matter Endocrinology Pharmacology
Citations 1
Registration NCT03866252
Key findings LSD-induced increases in white matter fractional anisotropy correlate with improvements in depressive symptoms in patients with major depressive disorder.

Abstract

The clinical trial NCT03866252 investigates the antidepressant effects of lysergic acid diethylamide (LSD) in 61 patients with major depressive disorder (MDD) randomized to low-dose LSD (LD-LSD; 2 × 25 μg) or moderate-to-high-dose LSD (HD-LSD; 100 μg followed by 200 μg) 4 weeks apart. Although the trial reports positive clinical outcomes, underlying mechanisms remain unclear. Here, we test whether LSD alters white matter (WM) microstructure, potentially reflecting enhanced neuroplasticity. Diffusion tensor imaging data from 35 patients (17 HD-LSD) include pre- and post-intervention scans. Voxel-wise permutation tests reveal group-by-time interactions, with increased fractional anisotropy (FA) in the internal and external capsule, sagittal stratum, and fornix/stria terminalis in the HD-LSD group. In this group, post-intervention FA values correlate with improvements in depressive symptoms at 2, 6, and 12 weeks, measured using the Inventory of Depressive Symptomatology (IDS-clinician rated [C] and IDS- self report [SR]). These findings suggest that LSD-induced WM microstructural changes are associated with antidepressant effects in MDD.

In the evidence

This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.

  • LSD-induced increases in white matter fractional anisotropy correlated with improvements in depressive symptoms at 2, 6, and 12 weeks.

    Synthesized

Comparable studies

Other randomized controlled trials on LSD for depression, most cited first.

Study Year Design Participants
Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Patients who experienced anxiety with or without association with a life-threatening... 2023 Randomized controlled trial n = 42
LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up. Patients with anxiety with or without life-threatening illness 2024 Randomized controlled trial n = 39
Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial. Patients with moderate-to-severe major depressive disorder 2025 Randomized controlled trial n = 61
LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder. Patients meeting DSM-5 criteria for major depressive disorder 2024 Randomized controlled trial
Reward-related neural activity after low doses of LSD in participants with depressed mood. Adults with subclinical mild-to-moderate depression (N=20) and controls with minimal... 2026 Randomized controlled trial n = 39

Explore topics

By condition and practice